Cargando…
Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node
BACKGROUND: Although the landmark INT-0116 trial and National Comprehensive Cancer Network (NCCN) guidelines recommended pT3-4Nx gastric cancer (GC) patients to receive chemoradiotherapy, the role of radiotherapy has not been distinguished from chemoradiotherapy. METHODS: GC with behavior of metasta...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653296/ https://www.ncbi.nlm.nih.gov/pubmed/33148125 http://dx.doi.org/10.1177/1533033820959400 |
_version_ | 1783607876577656832 |
---|---|
author | Zhi, Yunfei Lin, Zhousheng Ma, Jinyuan Mou, Weiming Chen, Xinhua |
author_facet | Zhi, Yunfei Lin, Zhousheng Ma, Jinyuan Mou, Weiming Chen, Xinhua |
author_sort | Zhi, Yunfei |
collection | PubMed |
description | BACKGROUND: Although the landmark INT-0116 trial and National Comprehensive Cancer Network (NCCN) guidelines recommended pT3-4Nx gastric cancer (GC) patients to receive chemoradiotherapy, the role of radiotherapy has not been distinguished from chemoradiotherapy. METHODS: GC with behavior of metastasis-indolent in lymph node (MILN) being confirmed with more than 15 examined LNs after gastrectomy were identified using the Surveillance, Epidemiology and End Result (SEER) database. The cancer-specific survival (CSS) of subgroups for radiotherapy, chemotherapy, chemoradiotherapy and non-adjuvant-treatment were compared. Propensity score matching (PSM) was performed between radiotherapy and non-radiotherapy subgroups to further distinguish the role of radiotherapy from chemoradiotherapy. Cox regression was performed to identify whether radiotherapy or chemotherapy could independently improve prognosis. RESULTS: We identified 690 MILN GC patients in SEER database. 5-year CSS was 71.9% in radiotherapy subgroup and 75.1% in non-radiotherapy subgroup(HR = 1.013, 95% CI = 0.714-1.438, p = 0.940), 75.6% in chemotherapy subgroup and 68.5% in non-chemotherapy subgroup(HR = 0.616, 95% CI = 0.430-0.884, p = 0.008), 52.5% in radiotherapy-alone subgroup and 71.9% in non-adjuvant treatment group (HR = 1.604, 95% CI = 0.575-4.471, p = 0.360), 72.9% in chemoradiotherapy subgroup and 79.5% in chemotherapy-alone subgroup (HR = 1.365, 95% CI = 0.859-2.172, p = 0.185), respectively. Further, PSM markedly improved balance of variables between radiotherapy subgroup and non-radiotherapy subgroup. After PSM, the role of the variables of radiotherapy and chemotherapy in contributing to improving CSS are consistent with that before PSM. Cox regression showed chemotherapy, tumor size, tumor invasiveness and Lauren classification were independent prognostic factors, but not including radiotherapy. CONCLUSIONS: Chemoradiotherapy confers superior prognosis to MILN GC patients compared with surgery alone might only be attributed to chemotherapy rather than radiotherapy. |
format | Online Article Text |
id | pubmed-7653296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-76532962020-11-19 Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node Zhi, Yunfei Lin, Zhousheng Ma, Jinyuan Mou, Weiming Chen, Xinhua Technol Cancer Res Treat Treatment for Advanced Gastric Cancer BACKGROUND: Although the landmark INT-0116 trial and National Comprehensive Cancer Network (NCCN) guidelines recommended pT3-4Nx gastric cancer (GC) patients to receive chemoradiotherapy, the role of radiotherapy has not been distinguished from chemoradiotherapy. METHODS: GC with behavior of metastasis-indolent in lymph node (MILN) being confirmed with more than 15 examined LNs after gastrectomy were identified using the Surveillance, Epidemiology and End Result (SEER) database. The cancer-specific survival (CSS) of subgroups for radiotherapy, chemotherapy, chemoradiotherapy and non-adjuvant-treatment were compared. Propensity score matching (PSM) was performed between radiotherapy and non-radiotherapy subgroups to further distinguish the role of radiotherapy from chemoradiotherapy. Cox regression was performed to identify whether radiotherapy or chemotherapy could independently improve prognosis. RESULTS: We identified 690 MILN GC patients in SEER database. 5-year CSS was 71.9% in radiotherapy subgroup and 75.1% in non-radiotherapy subgroup(HR = 1.013, 95% CI = 0.714-1.438, p = 0.940), 75.6% in chemotherapy subgroup and 68.5% in non-chemotherapy subgroup(HR = 0.616, 95% CI = 0.430-0.884, p = 0.008), 52.5% in radiotherapy-alone subgroup and 71.9% in non-adjuvant treatment group (HR = 1.604, 95% CI = 0.575-4.471, p = 0.360), 72.9% in chemoradiotherapy subgroup and 79.5% in chemotherapy-alone subgroup (HR = 1.365, 95% CI = 0.859-2.172, p = 0.185), respectively. Further, PSM markedly improved balance of variables between radiotherapy subgroup and non-radiotherapy subgroup. After PSM, the role of the variables of radiotherapy and chemotherapy in contributing to improving CSS are consistent with that before PSM. Cox regression showed chemotherapy, tumor size, tumor invasiveness and Lauren classification were independent prognostic factors, but not including radiotherapy. CONCLUSIONS: Chemoradiotherapy confers superior prognosis to MILN GC patients compared with surgery alone might only be attributed to chemotherapy rather than radiotherapy. SAGE Publications 2020-11-05 /pmc/articles/PMC7653296/ /pubmed/33148125 http://dx.doi.org/10.1177/1533033820959400 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Treatment for Advanced Gastric Cancer Zhi, Yunfei Lin, Zhousheng Ma, Jinyuan Mou, Weiming Chen, Xinhua Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node |
title | Distinguish the Role of Radiotherapy From Chemoradiotherapy for
Gastric Cancer With Behavior of Metastasis-Indolent in Lymph
Node |
title_full | Distinguish the Role of Radiotherapy From Chemoradiotherapy for
Gastric Cancer With Behavior of Metastasis-Indolent in Lymph
Node |
title_fullStr | Distinguish the Role of Radiotherapy From Chemoradiotherapy for
Gastric Cancer With Behavior of Metastasis-Indolent in Lymph
Node |
title_full_unstemmed | Distinguish the Role of Radiotherapy From Chemoradiotherapy for
Gastric Cancer With Behavior of Metastasis-Indolent in Lymph
Node |
title_short | Distinguish the Role of Radiotherapy From Chemoradiotherapy for
Gastric Cancer With Behavior of Metastasis-Indolent in Lymph
Node |
title_sort | distinguish the role of radiotherapy from chemoradiotherapy for
gastric cancer with behavior of metastasis-indolent in lymph
node |
topic | Treatment for Advanced Gastric Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653296/ https://www.ncbi.nlm.nih.gov/pubmed/33148125 http://dx.doi.org/10.1177/1533033820959400 |
work_keys_str_mv | AT zhiyunfei distinguishtheroleofradiotherapyfromchemoradiotherapyforgastriccancerwithbehaviorofmetastasisindolentinlymphnode AT linzhousheng distinguishtheroleofradiotherapyfromchemoradiotherapyforgastriccancerwithbehaviorofmetastasisindolentinlymphnode AT majinyuan distinguishtheroleofradiotherapyfromchemoradiotherapyforgastriccancerwithbehaviorofmetastasisindolentinlymphnode AT mouweiming distinguishtheroleofradiotherapyfromchemoradiotherapyforgastriccancerwithbehaviorofmetastasisindolentinlymphnode AT chenxinhua distinguishtheroleofradiotherapyfromchemoradiotherapyforgastriccancerwithbehaviorofmetastasisindolentinlymphnode |